Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. Summary
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
Real-time Euronext Bruxelles  -  11:28 2022-12-09 am EST
13.00 EUR   -0.91%
11/23Hyloris Pharmaceuticals Develops New Treatment For Idiopathic Rhinitis
MT
11/22Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis
GL
11/22Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
12/05/2022 12/06/2022 12/07/2022 12/08/2022 12/09/2022 Date
13.4(c) 13.4(c) 13.38(c) 13.12(c) 13(c) Last
1 749 238 2 239 2 711 2 076 Volume
-0.30% 0.00% -0.15% -1.94% -0.91% Change
More quotes
Estimated financial data (e)
Sales 2022 5,00 M 5,27 M 5,27 M
Net income 2022 -12,0 M -12,6 M -12,6 M
Net cash position 2022 26,0 M 27,4 M 27,4 M
P/E ratio 2022 -28,9x
Yield 2022 -
Sales 2023 11,0 M 11,6 M 11,6 M
Net income 2023 -9,60 M -10,1 M -10,1 M
Net cash position 2023 12,0 M 12,6 M 12,6 M
P/E ratio 2023 -36,1x
Yield 2023 -
Capitalization 348 M 367 M 367 M
EV / Sales 2022 64,5x
EV / Sales 2023 30,6x
Nbr of Employees 21
Free-Float 52,2%
More Financials
Company
Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives.... 
Sector
Pharmaceuticals
Calendar
03/16Earnings Release
More about the company
Ratings of Hyloris Pharmaceuticals SA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about HYLORIS PHARMACEUTICALS SA
11/23Hyloris Pharmaceuticals Develops New Treatment For Idiopathic Rhinitis
MT
11/22Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic..
GL
11/22Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic..
AQ
11/22Hyloris Pharmaceuticals SA Broadens Pipeline with A Nasal Product Candidate for Idiopat..
CI
10/12Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainabl..
GL
10/12Hyloris Pharmaceuticals Announces Move to LégiaPark Complex Aligned with its Sustainabl..
AQ
09/06Pleco Therapeutics B.V. announced that it has received €4.6 million in funding fro..
CI
09/06Pleco Therapeutics B.V. announced that it has received funding from Oost NL BV, Hyloris..
CI
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
09/01Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update
GL
09/01HYLORIS PHARMACEUTICALS SA : Half-year report
CO
09/01HYLORIS PHARMACEUTICALS SA : 1st-half-year results
CO
08/31Hyloris Pharmaceuticals : 2022 Half-year KPMG Report
PU
08/31Hyloris Pharmaceuticals : 2022 Half-year Report
PU
07/20Hyloris' Oral Mouth Rinse Shows Controlled Bleeding After Tooth Extraction in Early-sta..
MT
More news
News in other languages on HYLORIS PHARMACEUTICALS SA
11/23Hyloris Pharmaceuticals développe un nouveau traitement pour la rhinite idiopathique
11/22Hyloris voegt neusspray toe aan pijplijn
11/22Hyloris Pharmaceuticals Elargit son Portefeuille de Produits avec un Spray Nasal pour l..
11/22Hyloris Pharmaceuticals Elargit son Portefeuille de Produits avec un Spray Nasal pour l..
11/22Hyloris Pharmaceuticals SA élargit son portefeuille avec un produit candidat nasal pour..
More news
Chart HYLORIS PHARMACEUTICALS SA
Duration : Period :
Hyloris Pharmaceuticals SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HYLORIS PHARMACEUTICALS SA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 13,00 €
Average target price 20,00 €
Spread / Average Target 53,8%
EPS Revisions
Managers and Directors
Stijn van Rompay Chief Executive Officer & Executive Director
Jean-Luc Vandebroek Chief Financial Officer
Stefan Yee Chairman
Dietmar Aichhorn Chief Operating Officer
Marc Foidart Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HYLORIS PHARMACEUTICALS SA-24.16%371
JOHNSON & JOHNSON3.57%463 286
ELI LILLY AND COMPANY34.66%353 267
ABBVIE INC.22.59%293 450
PFIZER, INC.-14.92%290 657
NOVO NORDISK A/S22.08%287 434